Acurx Pharmaceuticals, Inc. (ACXP): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACXP Stock Price Chart Interactive Chart >
ACXP Price/Volume Stats
| Current price | $3.56 | 52-week high | $4.85 |
| Prev. close | $3.60 | 52-week low | $2.33 |
| Day low | $3.50 | Volume | 69,200 |
| Day high | $3.81 | Avg. volume | 39,367 |
| 50-day MA | $3.77 | Dividend yield | N/A |
| 200-day MA | $3.52 | Market Cap | 41.27M |
Acurx Pharmaceuticals, Inc. (ACXP) Company Bio
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Latest ACXP News From Around the Web
Below are the latest news stories about ACURX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACXP as an investment opportunity.
Presenting on the Emerging Growth Conference on January 25 Register NowMIAMI, Jan. 24, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 48th Emerging Growth Conference on January 25, 2022. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting companies |
Acurx Is Vying for Standard of Care in Treating Primary and Recurrent C. diffC. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United ... |
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023. This live, interactive online event will provide existing stockholders and the investment community with the opportunity to interact with the Company's President & Chief Executive Officer, |
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2022 Earnings Call TranscriptAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2022 Earnings Call Transcript November 14, 2022 Acurx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.32 EPS, expectations were $-0.28. Operator: Greetings. Welcome to Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022. At this time, all participants are in a listen-only mode. […] |
12 Best Biotech Stocks to Buy Under $10In this article, we discuss the 12 best biotech stocks to buy under $10. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy Under $10. The past two years have been challenging for the biotech sector, based on the market performance of biotech equities. Compared to […] |
ACXP Price Returns
| 1-mo | -16.04% |
| 3-mo | 20.27% |
| 6-mo | -9.18% |
| 1-year | -12.75% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -10.55% |
| 2022 | -7.90% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...